Skip to main content
Fig. 4 | Translational Medicine Communications

Fig. 4

From: Safety and efficacy of autologous non-hematopoietic enriched stem cell nebulization in COVID-19 patients: a randomized clinical trial, Abu Dhabi 2020

Fig. 4

Clinical improvement. Different trend line slopes during the clinical trial follow-up. Legend: Group A/S: Peripheral Blood Non-Hematopoietic Enriched Stem Cell Cocktail (PB- NHESC-C) Treated classified as severe; Group B/S: Controls classified as severe; Group A/M: PB-NHESC-C Treated classified as moderate; Group B/M: Controls classified as moderate

Back to article page